(272 days)
No
The description focuses on a standard immunoturbidimetric assay and does not mention any AI/ML components or data processing techniques indicative of AI/ML.
No.
The device is an in vitro diagnostic test used for the quantitative determination of specific light chains in serum and plasma, aiding in the diagnosis of certain conditions, but it does not treat or alleviate disease.
Yes
The intended use explicitly states that it is an "in vitro diagnostic test used for the quantitative determination of immunoglobulin bound and free kappa light chains (KAPPA) in serum and in Li-heparin plasma by immunoturbidimetry on Synchron LX20 System. Measurement of type of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus, in conjunction with other clinical and laboratory findings." The primary function of aiding in diagnosis categorizes it as a diagnostic device.
No
The device is an in vitro diagnostic test that relies on a chemical reaction and measurement of turbidity on a specific hardware system (Synchron LX20 System), indicating it is not software-only.
Yes, this device is an IVD (In Vitro Diagnostic).
The provided text explicitly states in both the "Intended Use / Indications for Use" and "Device Description" sections that the Kappa light chains assay is an in vitro diagnostic test.
N/A
Intended Use / Indications for Use
The Kappa light chains assay is an in vitro diagnostic test used for the quantitative determination of immunoglobulin bound and free kappa light chains (KAPPA) in serum and in Li-heparin plasma by immunoturbidimetry on Synchron LX20 System. Measurement of type of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus, in conjunction with other clinical and laboratory findings.
Product codes (comma separated list FDA assigned to the subject device)
DFH
Device Description
The Kappa light chains assay is an in vitro diagnostic test used for the quantitative determination of immunoglobulin bound and free kappa light chains (KAPPA) in serum and in Li-heparin plasma by immunoturbidimetry on Synchron LX20 System. Measurement of type of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus, in conjunction with other clinical and laboratory findings.
The determination of Kappa light chains is based on the specific turbidimetric reaction, which occurs between a polyclonal antiserum against human Immunoglobulin Kappa light chains and its corresponding antigen under optimal pH conditions and in the presence of polyethylene glycol (PEG). The turbidity of the immune complex is proportional to the concentration of the analyte in the sample.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Not Found
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Comparative performance studies were conducted using the Synchron LX20 System. Sentinel Kappa light chains on Synchron LX20 System method comparison yielded acceptable correlation with the Beckman Kappa light chain (K964260) on IMMAGE nephelometer Analyzer.
Method comparison: Kappa light chains assay on Synchron LX20 System was calibrator material with assigned Kappa Light chains concentration based on definition of Kappa Light chains as Whole IgG content (MW 150000). This comparison showed a correlation coefficient (r) of 0.985, slope of 0.900 and Y-intercept of 134 mg/dL. Conclusion: Data generated demonstrated an acceptable correlation between the Kappa Light chains assay on the Synchron LX20 System vs. the IMMAGE Immunochemistry System Kappa light chains (K964260) on IMMAGE nephelometer Analyzer.
Precision: Precision studies were conducted using Kappa light chains on the Synchron LX20 System. The found %CV values for 20x2x2 test (day x run x rep) on 6 levels (N=80 for each level) were:
Level 1 (Mean 125.7 mg/dL): Total Imprecision SD 8.55 mg/dL, CV% 6.8; Between days SD 6.88 mg/dL, CV% 5.5; Repeatability SD 5.08 mg/dL, CV% 4.1.
Level 2 (Mean 476.9 mg/dL): Total Imprecision SD 14.54 mg/dL, CV% 3.0; Between days SD 12.34 mg/dL, CV% 2.6; Repeatability SD 7.7 mg/dL, CV% 1.6.
Level 3 (Mean 93.5 mg/dL): Total Imprecision SD 5.63 mg/dL, CV% 6.0; Between days SD 3.33 mg/dL, CV% 3.6; Repeatability SD 3.44 mg/dL, CV% 3.7.
Level 4 (Mean 104.4 mg/dL): Total Imprecision SD 4.46 mg/dL, CV% 4.3; Between days SD 3.74 mg/dL, CV% 3.6; Repeatability SD 1.55 mg/dL, CV% 1.5.
Level 5 (Mean 651.9 mg/dL): Total Imprecision SD 25.27 mg/dL, CV% 3.9; Between days SD 22.40 mg/dL, CV% 3.4; Repeatability SD 11.69 mg/dL, CV% 1.8.
Level 6 (Mean 695.0 mg/dL): Total Imprecision SD 16.76 mg/dL, CV% 2.4; Between days SD 11.59 mg/dL, CV% 1.7; Repeatability SD 12.11 mg/dL, CV% 1.7.
Analytical Measurement Range (AMR): The found lower limit of the AMR of Lambda light chains on the Synchron LX20 System was 31.2 mg/dL. The found upper limit of the AMR was 750.13 mg/dL. The claimed AMR will be 35 to 750 mg/dL.
Conclusion for 510(k) Summary: These method comparison, precision and AMR data demonstrate that the analytical performance of the Kappa light chains on the Synchron LX20 System is substantially equivalent to IMMAGE Immunochemistry System Kappa light chain (K964260) on the IMMAGE nephelometer Analyzer.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s): If the device was cleared using the 510(k) pathway, identify the Predicate Device(s) K/DEN number used to claim substantial equivalence and list them here in a comma separated list exactly as they appear in the text. List the primary predicate first in the list.
Reference Device(s): Identify the Reference Device(s) K/DEN number and list them here in a comma separated list exactly as they appear in the text.
Not Found
Predetermined Change Control Plan (PCCP) - All Relevant Information for the subject device only (e.g. presence / absence, what scope was granted / cleared under the PCCP, any restrictions, etc).
Not Found
§ 866.5550 Immunoglobulin (light chain specific) immunological test system.
(a)
Identification. An immunoglobulin (light chain specific) immunological test system is a device that consists of the reagents used to measure by immunochemical techniques both kappa and lambda types of light chain portions of immunoglobulin molecules in serum, other body fluids, and tissues. In some disease states, an excess of light chains are produced by the antibody-forming cells. These free light chains, unassociated with gamma globulin molecules, can be found in a patient's body fluids and tissues. Measurement of the various amounts of the different types of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus.(b)
Classification. Class II (performance standards).
0
SFP = 3 2009
Page 2 of 5
510(k) Summary
Submitter's Name/Address SENTINEL CH. Via Robert Koch, 2 20152 Milan - Italv
Date of Preparation of this Summarv: Device Trade or Proprietary Name:
Classification Name:
Classification Number/Class: Product Code:
Contact Person Fabio Rota Technical Director +39 02 3455148 Fax: +39 02 34551464
July 10th , 2009 Kappa light chains Assay Immunoglobulin (light chain specific) immunological test system. Class II / 866.5550 DFH
This summary of 510(k) safety and effectiveness information is being submitted in accordance with the requirements of SMDA 1990 and 21 CFR 807.92.
The assigned 510(k) number is: K083602
Test Description:
The Kappa light chains assay is an in vitro diagnostic test used for the quantitative determination of immunoglobulin bound and free kappa light chains (KAPPA) in serum and in Li-heparin plasma by immunoturbidimetry on Synchron LX20 System. Measurement of type of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus, in conjunction with other clinical and laboratory findings.
The determination of Kappa light chains is based on the specific turbidimetric reaction, which occurs between a polyclonal antiserum against human Immunoglobulin Kappa light chains and its corresponding antigen under optimal pH conditions and in the presence of polyethylene glycol (PEG). The turbidity of the immune complex is proportional to the concentration of the analyte in the sample.
1
Substantial Equivalence:
The Kappa light chains assay is substantially equivalent to Beckman IMMAGE Immunochemistry System Kappa light chain (K964260) on the 1MMAGE nephelometer Analyzer. Both assays yield similar Performance Characteristics.
Similarities:
- Both assays are used for the quantitative determination of Kappa light chains (free and bound).
- Both assays are based on immunologic reaction between the Kappa light chains of human immunoglobulin and a specific polyclonal.
- Both assay detect bound and free Kappa light chains
- Both assays utilize reagents in R1 and R2 format.
- Both assays are traceable to ERM-DA 470 (European Reference Material) from BCR (EG Community Bureau of Reference), corresponding to RPPHS (Reference Preparation for Protein in Human Serum).
- Both assays yield similar clinical results.
Differences:
- The predicate device assay uses serum only as specimens. Sentinel assay uses serum and Li- heparin plasma.
- The predicate device quantificates Kappa light chains by nephelometry. Sentinel assay quantificates Kappa light chains by immunoturbidimetry.
- In the predicate device, Kappa values are given in mg/dL and expressed as "equivalent weight of the intact immunoglobulin molecules (IgG + IgA + IgM = Kappa + Lambda). Thus the Molecular Weight of the Light chains is considered to be 150000 dalton (as the MW of whole IgG).
- In the Sentinel assay, Kappa values are given in mg/dL and expressed as content of Immunoglobulin light chains. The Molecular Weight of the Light chains is estimated to be 25000 dalton. Therefore, the results on Beckman Immage are about 3 times higher than results on Synchron LX.
2
Intended Use:
The Kappa light chains assay is an in vitro diagnostic test used for the quantitative determination of immunoglobulin bound and free kappa light chains (KAPPA) in serum and in Li-heparin plasma by immunoturbidimetry on Synchron LX20 System. Measurement of type of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as theumatoid arthritis or systemic lupus erythematosus, in conjunction with other clinical and laboratory findings.
Performance Characteristics:
Comparative performance studies were conducted using the Synchron LX20 System. Sentinel Kappa light chains on Synchron LX20 System method comparison vielded acceptable correlation with the Beckman Kappa light chain (K964260) on IMMAGE nephelometer Analyzer.
Method comparison
Kappa light chains assay on Synchron LX20 System was calibrator material with assigned Kappa Light chains concentration based on definition of Kappa Light chains as Whole IgG content (MW 150000).
This comparison showed a correlation coefficient (r) of 0.985, slope of 0.900 and Y-intercept of 134 mg/dL.
Conclusion - Data generated demonstrated an acceptable correlation between the Kappa Light chains assay on the Synchron LX20 System vs. the IMMAGE Immunochemistry System Kappa light chains (K964260) on IMMAGE nephelometer Analyzer.
3
Precision:
| Mean
(mg/dL) | Total Imprecision | | Between days | | Repeatability
(Repeatibility) | |
|-----------------|-------------------|-----|---------------|-----|----------------------------------|-----|
| | SD
(mg/dL) | CV% | SD
(mg/dL) | CV% | SD
(mg/dL) | CV% |
| 125.7 | 8.55 | 6.8 | 6.88 | 5.5 | 5.08 | 4.1 |
| 476.9 | 14.54 | 3.0 | 12.34 | 2.6 | 7.7 | 1.6 |
| 93.5 | 5.63 | 6.0 | 3.33 | 3.6 | 3.44 | 3.7 |
| 104.4 | 4.46 | 4.3 | 3.74 | 3.6 | 1.55 | 1.5 |
| 651.9 | 25.27 | 3.9 | 22.40 | 3.4 | 11.69 | 1.8 |
| 695.0 | 16.76 | 2.4 | 11.59 | 1.7 | 12.11 | 1.7 |
Precision studies were conducted using Kappa light chains on the Synchron LX20 System. The found %CV values for 20x2x2 test (day x run x rep) on 6 levels (N=80 for each level) were:
Analytical Measurement Range (AMR):
The found lower limit of the AMR of Lambda light chains on the Synchron LX20 System was 31.2 mg/dL. The found upper limit of the AMR was 750.13 mg/dL.
The claimed AMR will be 35 to 750 mg/dL.
Conclusion for 510(k) Summary:
These method comparison, precision and AMR data demonstrate that the analytical performance of the Kappa light chains on the Synchron LX20 System is substantially equivalent to IMMAGE Immunochemistry System Kappa light chain (K964260) on the IMMAGE nephelometer Analyzer.
4
Image /page/4/Picture/0 description: The image shows the logo for the Department of Health & Human Services (HHS). The logo features a stylized image of an eagle with its wings spread, symbolizing protection and care. The text "DEPARTMENT OF HEALTH & HUMAN SERVICES • USA" is arranged in a circular pattern around the eagle, indicating the department's name and national affiliation. The logo is simple, using black lines on a white background.
Food and Drug Administration 10903 New Hampshire Avenue Document Mail Center - WO66-0609 Silver Spring, MD 20993-0002
SENTINEL CH SpA c/o Dr. Yangtse Portelles Regulatory Affairs Via Robert Koch, 2 20152 Milan Italy
SEP - 8 2009
Re: K083602
Trade/Device Name: Kappa Light Chains Assay Regulation Number: 21 CFR §866.5550 Regulation Name: Immunoglobulin (light chain specific) immunological test system Regulatory Class: Class II Product Code: DFH Dated: August 26, 2009 Received: August 31, 2009
Dear Dr. Portelles:
We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration. Iisting of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.
If your device is classified (see above) into class II (Special Controls), it may be subject to such additional controls. Existing major regulations affecting your device can be found in Title 21, Code of Federal Regulations (CFR), Parts 800 to 895. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set
5
Page 2 - Dr. Yangtse Portelles
forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.
If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to
http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.
You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.
Sincerely yours,
ia m chan
Maria M. Chan. Ph.D. Director Division of Immunology and Hematology Devices Office of In Vitro Diagnostic Device Evaluation and Safety Center for Devices and Radiological Health
Enclosure
6
Indications for Use
510(k) Number (if known): K083602
Device Name: Kappa light chains
Indications for Use:
The Kappa light chains assay is an in vitro diagnostic test used for the quantitative determination of immunoglobulin bound and free kappa light chains (KAPPA) in serum and in Li-heparin plasma by immunoturbidimetry on Synchron LX20 System. Measurement of type of light chains aids in the diagnosis of multiple myeloma (cancer of antibody-forming cells), lymphocytic neoplasms (cancer of lymphoid tissue), Waldenstrom's macroglobulinemia (increased production of large immunoglobulins), and connective tissue diseases such as rheumatoid arthritis or systemic lupus erythematosus, in conjunction with other clinical and laboratory findings.
Prescription Use X AND/OR (Part 21 CFR 801 Subpart D)
Over-The-Counter Use_ (21 CFR 801 Subpart C)
(PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED)
Concurrence of CDRH, Office of In Vitro Diagnostics Devices (OIVD)
Mana mchan
Division Sign-t
Office of In Vitro Diagnostic Device Evaluation and Safety
51000 KO 85602
Page 1 of 1